PTO/SB/08a (08-03)
Approved for use through 07/31/2005, OMB 0551-0031
U.S. Patent and Tradamark Office; U.S. DEPARTMENT OF COMMERCE

Papenyork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Application Number** 10/809,250 Filing Date March 25, 2004 First Named Inventor Heinz-Gerd Klaes et al Art Unit 1623 1814 Examiner Name To be assigned D. KHARE

(Use as many sheets as necessary) Attorney Docket Number 1/1477 Sheet

Examiner initials	Cite No.	Document Number	U. S. PATENT D  Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
muais	NO.	Number-Kind Code <sup>2 (7 known)</sup> US-	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		us-			<del></del>
	·	US-			
		US₊		· · · · · · · · · · · · · · · · · · ·	
		US-			<u> </u>
	·	US-			· · · · · · · · · · · · · · · · · · ·
		US-		· - · †	· · · · · · · · · · · · · · · · · · ·
		US-	<del></del>		· · · · · · · · · · · · · · · · · · ·
		US-			
		ús-			
		US-			<del></del>
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,			
Initials*	No.'	Country Code <sup>3</sup> 'Number <sup>4</sup> 'Kind Code <sup>8</sup> ( <i>it known</i> )	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Te		
au		WO 91/01137	02/07/1991	Harmenberg, Johan et al				
		WO 88/00050	01/14/1988	Astra Lakemedel Aktiebolag				
·		WO 99/41268	08/19/1999	Medivir AB				
		WO 2004/002433 A1	01/08/2004	Medivir AB	***************************************			
w		WO 99/09031	02/25/1999	Medivir AB	***************************************			

Examiner Signature	·dlesame	Date Considered	1/3/07	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Traistation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, P.O. Box 1450, Alanday, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 14498/PTO					Complete If Known		
					Application Number	10/809,250	
	INFO	RMATION D	DISCLO	SURE	Filing Date	March 25, 2004	
	STAT	EMENT BY	APPLI	CANT	First Named Inventor	Heinz-Gerd Klaes et al	
					Art Unit	1614	
_		(Use as many sheets	as necessary)		Examiner Name	To be assigned	
	Sheet	2	of	2	Attorney Docket Number	1/1477	

NON PATENT LITERATURE DOCUMENTS						
Examiner nitials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T			
ou 1		CLERCQ DE E; HIV Inhibitors Targeted at the Reverse Transcriptase; Aids Research and Human Retroviruses Vol. 8 No. 2 (1992) pages 119-134; Mary Ann Llebert, Inc. Publishers				
	·····	KITAMURA, TAKASHI; Abstract Database Accession No. 1995-184187; Chemotherapy of AIDS - Living with HIV; Immunology Frontier Vol. 4 No. 5 (1994) pages 393-398				
		MAGA, G. ET AL; Molecular basis for the enantioselectivity of HIV-1 reverse transcriptase: role of the 3'-hydroxyl group of the L-(beta)-ribose in chiral discrimination between D-and L-enantiomers of deoxy- and dideoxy-nucleoside triphosphate analogs; Necleic Acids Research (1999) Vol. 27 No. 4 pages 972-978; Oxford University Press				
du		International Search Report Reference No. PCT/US2004/008736				
	***********					
	***************************************		<b></b>			
	*************					
	••••••••		ļ			
!******	**********					
			ļ			

Examiner Signature	dulane	Date Considered	1/3/07

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.